Differentiation therapy for solid tumors

Journal of Digestive Diseases

Volumn 15, Issue 4, 2014, Pages 159-165

  Xu, Wen Ping ^a   Zhang, Xin ^a   Xie, Wei Fen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Differentiation therapy; Epigenetics; Neoplastic stem cell; Solid tumor; Transcription factor

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; DEACETYLATION; DIFFERENTIATION THERAPY; EPIGENETICS; HUMAN; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR GROWTH;

DIFFERENTIATION THERAPY; EPIGENETICS; NEOPLASTIC STEM CELL; SOLID TUMOR; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; EPIGENESIS, GENETIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; TRANSCRIPTION FACTORS;

EID: 84896289524     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12122     Document Type: Article

References (66)

1. Cruz FD, Matushansky I. Solid tumor differentiation therapy - is it possible? Oncotarget 2012; 3: 559-567.
2. Pierce GB Jr, Verney EL. An in vitro and in vivo study of differentiation in teratocarcinomas. Cancer 1961; 14: 1017-1029.
3. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113: 3655-3665.
4. Huang ME, Ye YC, Chen SR etal. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Haematol Blood Transfus 1989; 32: 88-96.
5. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003; 3: 338-343.
6. Pettersson F, Miller WH Jr, Nervi C etal. The 12th International Conference on Differentiation Therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells. Cell Death Differ 2011; 18: 1231-1233.
7. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006; 17: 1620-1624.
8. Lim YC, Kang HJ, Kim YS, Choi EC. All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway. Eur J Cancer 2012; 48: 3310-3318.
9. Kazanjian A, Shroyer NF. NOTCH signaling and ATOH1 in colorectal cancers. Curr Colorectal Cancer Rep 2011; 7: 121-127.
10. Pham PV, Phan NL, Nguyen NT etal. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 2011; 9: 209.
11. Desbordes SC, Placantonakis DG, Ciro A etal. High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells. Cell Stem Cell 2008; 2: 602-612.
12. Gupta PB, Onder TT, Jiang G etal. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
13. Mezencev R, Wang L, McDonald JF. Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening. J Ovarian Res 2012; 5: 30.
14. Hothi P, Martins TJ, Chen L etal. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 2012; 3: 1124-1136.
15. Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475: 390-393.
16. Huang P, He Z, Ji S etal. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389.
17. Yu B, He ZY, You P etal. Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors. Cell Stem Cell 2013; 13: 328-340.
18. Nakajima H. Role of transcription factors in differentiation and reprogramming of hematopoietic cells. Keio J Med 2011; 60: 47-55.
19. Costa RH, Kalinichenko VV, Holterman AX, Wang X. Transcription factors in liver development, differentiation, and regeneration. Hepatology 2003; 38: 1331-1347.
20. Odom DT, Zizlsperger N, Gordon DB etal. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004; 303: 1378-1381.
21. Hatziapostolou M, Polytarchou C, Aggelidou E etal. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011; 147: 1233-1247.
22. Yin C, Lin Y, Zhang X etal. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene. Hepatology 2008; 48: 1528-1539.
23. Yin C, Wang PQ, Xu WP etal. Hepatocyte nuclear factor-4α reverses malignancy of hepatocellular carcinoma through regulating miR-134 in the DLK1-DIO3 region. Hepatology 2013; 58: 1964-1976.
24. Ning BF, Ding J, Yin C etal. Hepatocyte nuclear factor 4α suppresses the development of hepatocellular carcinoma. Cancer Res 2010; 70: 7640-7651.
25. Yue HY, Yin C, Hou JL etal. Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats. Gut 2010; 59: 236-246.
26. Fan TT, Hu PF, Wang J etal. Regression effect of hepatocyte nuclear factor 4α on liver cirrhosis in rats. J Dig Dis 2013; 14: 318-327.
27. Zeng X, Lin Y, Yin C etal. Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice. Hepatology 2011; 54: 2036-2047.
28. Shi YC, Zhao H, Yin C etal. C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades. Dig Liver Dis 2013; 45: 844-851.
29. Fukazawa T, Matsuoka J, Yamatsuji T, Maeda Y, Durbin ML, Naomoto Y. Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int J Mol Med 2010; 25: 3-10.
30. Ortiz R, Melguizo C, Prados J etal. New gene therapy strategies for cancer treatment: a review of recent patents. Recent Pat Anticancer Drug Discov 2012; 7: 297-312.
31. Melchiorri D, Pani L, Gasparini P etal. Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat Rev Drug Discov 2013; 12: 719.
32. Ye D, Xu D, Singer AU, Juliano RL. Evaluation of strategies for the intracellular delivery of proteins. Pharm Res 2002; 19: 1302-1309.
33. Stock K, Nolden L, Edenhofer F, Quandel T, Brüstle O. Transcription factor-based modulation of neural stem cell differentiation using direct protein transduction. Cell Mol Life Sci 2010; 67: 2439-2449.
34. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
35. Siddiqi S, Mills J, Matushansky I. Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas. Curr Stem Cell Res Ther 2010; 5: 63-73.
36. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184: 1-16.
37. Nalabothula N, Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 2011; 3: 145-155.
38. O'Connor OA, Heaney ML, Schwartz L etal. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24: 166-173.
39. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 2013; 7: 47-60.
40. Lim LP, Lau NC, Garrett-Engele P etal. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773.
41. Silber J, Lim DA, Petritsch C etal. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008; 6: 14.
42. Taulli R, Bersani F, Foglizzo V etal. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366-2378.
43. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 2009; 119: 2119-2123.
44. Bu P, Chen KY, Chen JH etal. A microRNA miR-34a-regulated bimodal switch targets notch in colon cancer stem cells. Cell Stem Cell 2013; 12: 602-615.
45. Wu Y, Liu S, Xin H etal. Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer 2011; 117: 3989-3998.
46. Yu Y, Sarkar FH, Majumdar AP. Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 2013; 6: 180-186.
47. Ji J, Yamashita T, Budhu A etal. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009; 50: 472-480.
48. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004; 24: 201-221.
49. Kawamata H, Tachibana M, Fujimori T, Imai Y. Differentiation-inducing therapy for solid tumors. Curr Pharm Des 2006; 12: 379-385.
50. Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 2013; 19: 1651-1659.
51. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
52. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 2004; 5: 419-429.
53. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F; German and Austrian Adrenal Network. Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 2005; 90: 3886-3896.
54. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer. Cancer Lett 2006; 240: 225-233.
55. Demetri GD, Fletcher CD, Mueller E etal. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999; 96: 3951-3956.
56. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-1412.
57. Januchowski R, Wojtowicz K, Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother 2013; 67: 669-680.
58. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 2002; 8: 1206-1212.
59. David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther 2010; 9: 678-684.
60. Bachman JW, Hillen T. Mathematical optimization of the combination of radiation and differentiation therapies for cancer. Front Oncol 2013; 3: 52.
61. Sung MW, Waxman S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res 2007; 27: 995-1001.
62. Vainstein V, Kirnasovsky OU, Kogan Y, Agur Z. Strategies for cancer stem cell elimination: insights from mathematical modeling. J Theor Biol 2012; 298: 32-41.
63. Ferrara FF, Fazi F, Bianchini A etal. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2-7.
64. Aguda BD. Modeling microRNA-transcription factor networks in cancer. Adv Exp Med Biol 2013; 774: 149-167.
65. Schulz WA, Hoffmann MJ. Transcription factor networks in embryonic stem cells and testicular cancer and the definition of epigenetics. Epigenetics 2007; 2: 37-42.
66. Aghdassi A, Sendler M, Guenther A etal. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 2012; 61: 439-448.